Metformin Extended Release Versus Metformin Immediate Release in Subjects With Type 2 Diabetes

PHASE4CompletedINTERVENTIONAL
Enrollment

532

Participants

Timeline

Start Date

December 31, 2014

Primary Completion Date

November 30, 2015

Study Completion Date

April 30, 2016

Conditions
Diabetes Mellitus, Type 2
Interventions
DRUG

Metformin IR

Subjects will receive Metformin Immediate Release (IR) tablets, orally once daily at a dose of 500 milligram (mg) for 1 week, and then dose will increase with increments of 500 mg every week in first 2 weeks to 1500 mg. After that dose will increase up to maximum dose of 2000 mg for the next 2 weeks and will be maintained at 2000 mg until Week 16.

DRUG

Metformin XR

Subjects will receive Metformin Extended Release (XR) tablets, orally once daily at a dose of 500 mg for 1 week, and then dose will increase with increments of 500 mg every week in first 2 weeks to 1500 mg. After that dose will increase up to maximum dose of 2000 mg for the next 2 weeks and will be maintained at 2000 mg until Week 16.

Trial Locations (1)

Unknown

Please contact the Merck KGaA Communication Center, Darmstadt

All Listed Sponsors
lead

Merck KGaA, Darmstadt, Germany

INDUSTRY

NCT02252965 - Metformin Extended Release Versus Metformin Immediate Release in Subjects With Type 2 Diabetes | Biotech Hunter | Biotech Hunter